MCID: PYL005
MIFTS: 56

Pyelonephritis

Categories: Nephrological diseases

Aliases & Classifications for Pyelonephritis

Summaries for Pyelonephritis

MalaCards based summary : Pyelonephritis is related to pyelitis and acute cystitis. An important gene associated with Pyelonephritis is TLR4 (Toll Like Receptor 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cefixime and Ceftriaxone have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 72 Pyelonephritis is inflammation of the kidney, typically due to a bacterial infection. Symptoms most... more...

Related Diseases for Pyelonephritis

Diseases in the Pyelonephritis family:

Chronic Pyelonephritis Acute Pyelonephritis

Diseases related to Pyelonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 472)
# Related Disease Score Top Affiliating Genes
1 pyelitis 32.4 CRP CXCR1 TLR4
2 acute cystitis 31.8 ALB CCL2 CRP CXCL8 IL6
3 cystitis 31.3 CRP CXCL8 IL6 TLR4 TNF UMOD
4 acute pyelonephritis 31.0 ALB CRP CXCL8 CXCR1 CXCR2 IL10
5 hydronephrosis 30.5 ALB CCL2 NAGLU
6 pyuria 30.3 ALB CRP CXCL8
7 fasciitis 30.2 CXCL8 IL6 TNF
8 spinal cord injury 29.9 CXCL8 IL6 TNF
9 septic arthritis 29.9 CRP CXCL8 TLR4
10 infective endocarditis 29.8 CRP IL6 TNF
11 interstitial nephritis 29.8 ACE ALB CRP UMOD
12 vaginitis 29.7 CXCL8 IL1B IL6
13 spondylitis 29.7 CRP IL6 TNF
14 haemophilus influenzae 29.6 CXCL8 IL1B TNF
15 bronchitis 29.6 ALB CXCL8 TNF
16 myeloma, multiple 29.6 ALB CXCL8 IL6
17 salmonellosis 29.5 ALB IL1B TLR4
18 bacteriuria 29.5 CXCL8 CXCR1 CXCR2 IL6 TLR4
19 cerebral palsy 29.5 IL1B IL6 TNF
20 acute kidney tubular necrosis 29.5 ALB NAGLU UMOD
21 posterior urethral valves 29.5 ACE IL6 TNF
22 cholangitis 29.5 ALB CRP IL6 TNF
23 glomerulonephritis 29.4 ALB CCL2 IL1B
24 endometriosis 29.3 CCL2 CXCL8 IL1B IL6
25 eclampsia 29.3 ALB PGF TNF
26 autosomal dominant polycystic kidney disease 29.3 ACE ALB CCL2
27 kidney disease 29.3 ACE ALB NAGLU UMOD
28 prostatitis 29.3 CXCL8 IL10 IL1B IL6 TNF
29 urinary tract obstruction 29.1 ALB CCL2 NAGLU UMOD
30 diabetes mellitus 29.1 ACE ALB CRP IL1B IL6 TNF
31 osteomyelitis 29.1 CXCL8 IL10 IL1B IL6 TNF
32 melioidosis 29.1 IL10 IL6 TLR4 TNF
33 mycobacterium tuberculosis 1 29.0 CXCR2 IL10 TLR4 TNF
34 chronic kidney failure 29.0 ACE ALB CRP IL6 UMOD
35 adult respiratory distress syndrome 28.8 ACE CXCL8 IL10 IL6 TNF
36 heart disease 28.7 ACE ALB CRP IL6 TNF
37 arthritis 28.6 CCL2 CXCL8 IL10 IL1B IL6 TNF
38 arteriosclerosis 28.6 ACE CCL2 CRP IL10 IL6
39 colitis 28.6 CXCL8 IL10 IL1B IL6 TLR4 TNF
40 brucellosis 28.6 CRP CXCL8 IL10 IL6 TLR4 TNF
41 end stage renal failure 28.6 ACE ALB CRP IL6 TNF UMOD
42 endocarditis 28.5 ALB CRP CXCL8 IL10 IL6 TNF
43 kawasaki disease 28.4 ALB CCL2 CRP IL10 IL6 TNF
44 crohn's disease 28.4 CRP IL10 IL1B IL6 TLR4 TNF
45 appendicitis 28.3 ALB CRP CXCL8 IL10 IL1B IL6
46 pneumonia 28.2 CCL2 CRP CXCL8 IL10 IL1B IL6
47 gastroenteritis 28.1 ALB CRP CXCL8 IL10 IL1B IL6
48 rheumatoid arthritis 27.9 CCL2 CRP CXCL8 IL10 IL1B IL6
49 systemic lupus erythematosus 27.6 ALB CCL2 CRP IL10 IL1B IL6
50 xanthogranulomatous pyelonephritis 12.2

Comorbidity relations with Pyelonephritis via Phenotypic Disease Network (PDN): (show all 22)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Chronic Kidney Failure Chronic Myocardial Ischemia
Cystitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hydronephrosis
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Kidney Disease
Nephrolithiasis, X-Linked Recessive, with Renal Failure Osteoporosis
Paralytic Ileus Protein-Energy Malnutrition
Schizophreniform Disorder Ureterolithiasis

Graphical network of the top 20 diseases related to Pyelonephritis:



Diseases related to Pyelonephritis

Symptoms & Phenotypes for Pyelonephritis

GenomeRNAi Phenotypes related to Pyelonephritis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 IL10 IL1B TNF UMOD ACE CXCL8
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CXCL8 IL10 IL1B TNF UMOD ACE

MGI Mouse Phenotypes related to Pyelonephritis:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 CXCR2 IL10 IL1B IL6 NAGLU PGF
2 immune system MP:0005387 10.18 CXCR1 CXCR2 IL10 IL1B IL6 NAGLU
3 growth/size/body region MP:0005378 10.16 ACE CXCR2 IL10 IL1B IL6 NAGLU
4 homeostasis/metabolism MP:0005376 10.14 TNF UMOD ACE ALB CRP CXCR2
5 hematopoietic system MP:0005397 10.09 ACE CXCR1 CXCR2 IL10 IL1B IL6
6 adipose tissue MP:0005375 9.97 ACE IL6 PGF TLR4 TNF UMOD
7 liver/biliary system MP:0005370 9.92 ACE ALB CXCR2 IL10 IL6 NAGLU
8 neoplasm MP:0002006 9.91 ACE ALB CXCR2 IL10 IL1B IL6
9 renal/urinary system MP:0005367 9.7 ACE ALB CXCR2 IL6 NAGLU TLR4
10 skeleton MP:0005390 9.56 UMOD CXCR2 IL10 IL1B IL6 NAGLU
11 vision/eye MP:0005391 9.17 CXCR2 IL10 IL6 NAGLU PGF TLR4

Drugs & Therapeutics for Pyelonephritis

Drugs for Pyelonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefixime Approved, Investigational Phase 4,Phase 1 79350-37-1 5362065 54362
2
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
3
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
4
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
5
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
6
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3 67-20-9 5353830
7
Sulfamethoxazole Approved Phase 4,Phase 3 723-46-6 5329
8
Trimethoprim Approved, Vet_approved Phase 4,Phase 3 738-70-5 5578
9
Fosfomycin Approved Phase 4,Phase 2,Phase 3 23155-02-4 446987
10
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
11
Cilastatin Approved, Investigational Phase 4,Phase 2 82009-34-5 6435415 5280454
12
Imipenem Approved Phase 4,Phase 2 64221-86-9, 74431-23-5 104838
13
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
14
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
15
Cefoxitin Approved Phase 4 35607-66-0 441199
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 4,Phase 3 58-05-9 143 6006
18 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
20 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Antitubercular Agents Phase 4,Phase 3
22 Fluoroquinolones Phase 4,Phase 2
23 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2
24 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
25 HIV Protease Inhibitors Phase 4,Phase 2
26
protease inhibitors Phase 4,Phase 2
27 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Phase 2
28 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
29 Renal Agents Phase 4,Phase 3,Phase 2
30 Antimalarials Phase 4,Phase 3
31 Antiparasitic Agents Phase 4,Phase 3
32 Antiprotozoal Agents Phase 4,Phase 3
33 Folic Acid Antagonists Phase 4,Phase 3
34 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4,Phase 3
35 Vitamin B Complex Phase 4,Phase 3
36 Lactams Phase 4
37 Amdinocillin Pivoxil Phase 4
38 Folate Nutraceutical Phase 4,Phase 3
39 Vitamin B9 Nutraceutical Phase 4,Phase 3
40 Uva-ursi Nutraceutical Phase 4
41
Ertapenem Approved, Investigational Phase 3,Phase 2 153832-46-3 150610
42
Meropenem Approved, Investigational Phase 3,Phase 2,Phase 1 119478-56-7 441130 64778
43
Piperacillin Approved Phase 3,Phase 2 66258-76-2 43672
44
Tazobactam Approved Phase 3,Phase 2 89786-04-9 123630
45 Avibactam Approved Phase 3,Phase 2 1192500-31-4
46
Ceftazidime Approved Phase 3,Phase 2 72558-82-8, 78439-06-2 5481173
47
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
48
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
49
Colistin Approved Phase 3 1066-17-7, 1264-72-8 5311054
50
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021

Interventional clinical trials:

(show top 50) (show all 96)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety Study of Short-term Antibiotic for Pyelonephritis in Women Completed NCT01390623 Phase 4 Ceftriaxone
2 Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old Completed NCT00136656 Phase 4 antibiotic;antibiotics
3 Treatment's Duration of Acute Uncomplicated Pyelonephritis Completed NCT00873626 Phase 4 levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)
4 A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux Completed NCT00382343 Phase 4 Sulfamethoxazole/trimethoprim
5 Pharmacokinetics of Ciprofloxacin in Pediatric Patients Completed NCT02598362 Phase 4 ciprofloxacin
6 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Completed NCT02246361 Phase 4
7 Febrile Urinary Tract Infection Randomized Short Treatment Trial Completed NCT00809913 Phase 4 short treatment (ciprofloxacin)
8 Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aerugi Completed NCT00481689 Phase 4 Cipro XR (Ciprofloxacin, BAYQ3939)
9 A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections Completed NCT01763008 Phase 4 No intervention
10 Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis Recruiting NCT03179384 Phase 4 Ceftriaxone
11 Treating Pyelonephritis an Urosepsis With Pivmecillinam Recruiting NCT03282006 Phase 4 pivmecillinam
12 Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial Recruiting NCT03151603 Phase 4 Arctuvan;Fosfomycin;Placebo to Arctuvan;Placebo to Fosfomycin
13 The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria Recruiting NCT01871753 Phase 4
14 Management of Sub-Clinical Bacteriuria in Pregnancy Not yet recruiting NCT03275623 Phase 4 Antibiotic
15 Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin Terminated NCT00239161 Phase 4 Levofloxacin
16 Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli Terminated NCT02474706 Phase 4 Cefoxitin;imipenem
17 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
18 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
19 Contrast-Enhanced US of Spleen, Liver and Kidney Unknown status NCT00190281 Phase 3
20 Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis Completed NCT00210990 Phase 3 doripenem
21 Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis Completed NCT00229021 Phase 3 doripenum
22 Efficacy, Safety, Tolerability of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Complicated Urinary Tract Infections (cUTIs), Including Acute Pyelonephritis (AP), in Adults Completed NCT02166476 Phase 3 Meropenem-Vaborbactam;Piperacillin-Tazobactam;Levofloxacin;Saline
23 Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis Completed NCT01345929 Phase 3 CXA-201;Levofloxacin
24 A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis. Completed NCT00210886 Phase 3 levofloxacin
25 Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014) Completed NCT02728089 Phase 3 MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
26 Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) Completed NCT01599806 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
27 Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) Completed NCT01595438 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
28 A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) Completed NCT02486627 Phase 3 plazomicin;meropenem;levofloxacin (oral)
29 Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections Completed NCT02753946 Phase 2, Phase 3 ZTI-01;Piperacillin-tazobactam
30 A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED) Completed NCT00379964 Phase 3 caspofungin acetate
31 A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048) Completed NCT00379951 Phase 3 ertapenem sodium
32 Efficacy, Safety, Tolerability of Carbavance Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults Completed NCT02168946 Phase 3 Carbavance;Best Available Therapy
33 Queen's University Investigation of Calcification in Chronic Kidney Disease Completed NCT00687661 Phase 3 Bisphosphonate;Placebo
34 A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections Completed NCT00258089 Phase 3 Levofloxacin
35 A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
36 Evaluation of the Efficiency of Autologous Adipocytes Graft in Endoscopic Treatment in Vesico-Renal Reflux in Children Recruiting NCT00367159 Phase 3
37 Short-term Antibiotic Therapy for Pyelonephritis in Childhood Terminated NCT00724256 Phase 3 ceftibuten;ceftibuten
38 A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections Terminated NCT01110408 Phase 3 Doripenem;Doripenem placebo;Cefepime;Cefepime placebo;Amoxicillin/clavulanate potassium
39 An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections Terminated NCT02302092 Phase 3 Flomoxef;Cefepime
40 Efficacy of Antimicrobial Prophylaxis for Shock Wave Lithotripsy (SWL) on Reducing Urinary Tract Infection (UTI) Terminated NCT01873690 Phase 3 Ciprofloxacin;Placebo
41 Antibiotic Prophylaxis in Children With Pyelonephritis Withdrawn NCT00752375 Phase 3 Trimethoprim Sulfamethoxazole;placebo
42 Different Modes of Temperature Measurement in the Emergency Department Withdrawn NCT01801020 Phase 3
43 Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli Unknown status NCT02537847 Phase 2 Sitafloxacin;Ertapenem
44 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Enbrel subcutaneously at Week 12;Efficacy of Enbrel subcutaneously at Week 24;Efficacy of Enbrel subcutaneously at Week 36;Efficacy of Enbrel subdermally at Week 12;Efficacy of Enbrel subdermally at Week 24;Efficacy of Enbrel subdermally at Week 36;PASI 75 n(%) subcutaneously at Week 12;PASI 75 n(%) subcutaneously at Week 24;PASI 75 n(%) subcutaneously at Week 36;PASI 75 n(%) subdermally at Week 12;PASI 75 n(%) subdermally at Week 24;PASI 75 n(%) subdermally at Week 36;Adverse Reactions of Enbrel subcutaneously;Adverse Reactions of Enbrel subdermally at Week 36;Gadolinium;Gadolinium;Gadolinium
45 Effect of Acetylcysteine in Pediatric Acute Pyelonephritis. Completed NCT02080182 Phase 2 Acetylcysteine;placebo acetylcysteine
46 Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Completed NCT01928433 Phase 2 Finafloxacin 800 mg i.v. once daily;Finafloxacin placebo i.v. once daily;Finafloxacin 800 mg tablets once daily;Finafloxacin placebo tablets once daily;Ciprofloxacin 400 mg i.v. twice daily;Ciprofloxacin placebo i.v. twice daily;Ciprofloxacin 500 mg oral twice daily;Ciprofloxacin placebo oral twice daily
47 Study of Plazomicin (ACHN-490) Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis Completed NCT01096849 Phase 2 levofloxacin;plazomicin;placebo
48 Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections Completed NCT00921024 Phase 2 CXA-101;Ceftazidime
49 A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections Completed NCT02321800 Phase 2 S-649266;Imipenem/cilastatin
50 Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003) Completed NCT01505634 Phase 2 MK-7655 250 mg;MK-7655 125 mg;imipenem/cilastatin 500 mg;Placebo to MK-7655;Ciprofloxacin

Search NIH Clinical Center for Pyelonephritis

Cochrane evidence based reviews: pyelonephritis

Genetic Tests for Pyelonephritis

Genetic tests related to Pyelonephritis:

# Genetic test Affiliating Genes
1 Pyelonephritis 28

Anatomical Context for Pyelonephritis

MalaCards organs/tissues related to Pyelonephritis:

38
Kidney, Testes, Liver, Neutrophil, Bone, Colon, Prostate

Publications for Pyelonephritis

Articles related to Pyelonephritis:

(show top 50) (show all 1797)
# Title Authors Year
1
The clinical impact of bacteremia on outcomes in elderly patients with pyelonephritis or urinary sepsis: A prospective multicenter study. ( 29364923 )
2018
2
Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: A Multicenter, Randomized, Double-Blind, Phase 2 Study. ( 29378708 )
2018
3
Colonization of preservation solution in kidney transplantation: Clinical impact and risk of secondary acute graft pyelonephritis. ( 29395835 )
2018
4
The use of cefepime as a carbapenem-sparing antibiotic for treating uncomplicated acute pyelonephritis caused by extended-spectrum I^-lactamase producing Escherichia coli. ( 29086602 )
2018
5
A rare case of renal vein thrombosis secondary to<i>Klebsiella pneumoniae</i>pyelonephritis. ( 29416285 )
2018
6
Pyelonephritis in Dogs: Retrospective Study of 47 Histologically Diagnosed Cases (2005-2015). ( 29197113 )
2018
7
D-dimer as a marker of acute pyelonephritis in infants younger than 24A months with urinary tract infection. ( 29306986 )
2018
8
Useful Predictive Factors for Bacteremia among Outpatients with Pyelonephritis. ( 29321419 )
2018
9
Emphysematous pyelonephritis. ( 29445494 )
2018
10
Acute Pyelonephritis in Adults. ( 29298155 )
2018
11
Risk Factors for Uroseptic Shock in Patients with Urolithiasis-Related Acute Pyelonephritis. ( 29065405 )
2018
12
Renal vein thrombosis complicating severe acute pyelonephritis with renal abscesses and associated bacteraemia caused by extended-spectrum beta-lactamase producing Escherichia coli. ( 29327131 )
2018
13
Overuse of Diagnostic Testing in the Management of Korean Patients with Acute Pyelonephritis. ( 28332347 )
2017
14
The climate impact on female acute pyelonephritis in Taiwan: AA population-based study. ( 28805597 )
2017
15
C5aR1 promotes acute pyelonephritis induced by uropathogenic E. coli. ( 29263309 )
2017
16
Emphysematous Pyelonephritis Treated with Vacuum Sealing Drainage. ( 28091422 )
2017
17
Xanthogranulomatous pyelonephritis presenting as a type IV renal cyst. ( 28522934 )
2017
18
Deriving a management algorithm for emphysematous pyelonephritis: Can we rely on minimally invasive strategies or should we be opting for earlier nephrectomy? ( 28933020 )
2017
19
Emphysematous pyelonephritis: Changing trend of clinical spectrum, pathogenesis, management and outcome. ( 28717547 )
2017
20
Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum I^-lactamase-producing Escherichia coli. ( 28263710 )
2017
21
Follow-up of acute pyelonephritis: what causes the diffusion-weighted magnetic resonance imaging recovery to lag clinical recovery? ( 28660334 )
2017
22
Emphysematous Pyelonephritis with Human Immunodeficiency Virus Infection. ( 28571161 )
2017
23
Xanthogranulomatous Pyelonephritis with Incomplete Double Ureter. ( 29075296 )
2017
24
Plasmatic presepsin (sCD14-ST) concentrations in acute pyelonephritis in adult patients. ( 27889429 )
2017
25
Splenic Abscess After Acute Pyelonephritis. ( 28215950 )
2017
26
High-grade transitional cell carcinoma masquerading as a xanthogranulomatous pyelonephritis and perinephric abscess. ( 28491170 )
2017
27
Massive Renal Replacement Lipomatosis With Foci of Xanthogranulomatous Pyelonephritis in a Horseshoe Kidney. ( 28443241 )
2017
28
Prevention of Renal Scarring in Acute Pyelonephritis by Probiotic Therapy: an Experimental Study. ( 29204797 )
2017
29
An Interesting Case of Recurrent Pyelonephritis. ( 29313584 )
2017
30
Ultrasonography of acute flank pain: a focus on renal stones and acute pyelonephritis. ( 29382187 )
2017
31
Acute leukemia masquerading as xanthogranulomatous pyelonephritis. ( 28479773 )
2017
32
A randomized controlled trial of sitafloxacin vs. ertapenem as a switchA therapy after treatment for acute pyelonephritis caused by extended-spectrum I^-lactamase-producing Escherichia coli: A pilot study. ( 28587974 )
2017
33
Spontaneous Nephrocutaneous Fistula: Rare Complication of Xanthogranulomatous Pyelonephritis. ( 28138432 )
2017
34
Electrolyte and Acid-Base Abnormalities in Infants with Community-Acquired Acute Pyelonephritis: Prospective Cross-Sectional Study. ( 28697495 )
2017
35
Concurrent Diffuse Pyelonephritis and Prostatitis: Discordant Findings on Sequential FDG PET/CT and 67Ga SPECT/CT Imaging. ( 27824318 )
2017
36
Xanthogranulomatous Pyelonephritis Manifesting as a Nephrocutaneous Fistula in a 5-Year-Old Female. ( 28131924 )
2017
37
Pyelonephritis due to Brucella species: true clinical entity or ghost disease? ( 27909584 )
2017
38
Adenovirus pyelonephritis in the late posttransplant period. ( 28709609 )
2017
39
18F-FDG PET/CT in Renal Infections: Evidence of Acute Pyelonephritis in a Horseshoe Kidney. ( 27879491 )
2017
40
Early Progression of Xanthogranulomatous Pyelonephritis in Children Might Be Dependent on Vimentin Expression. ( 28978905 )
2017
41
Performance of qSOFA and SOFA for predicting mortality in patients with acute pyelonephritis associated with upper urinary tract calculi. ( 29291417 )
2017
42
Exploring the Anti-quorum Sensing and Antibiofilm Efficacy of Phytol against<i>Serratia marcescens</i>Associated Acute Pyelonephritis Infection in Wistar Rats. ( 29259923 )
2017
43
Xanthogranulomatous pyelonephritis in a paediatric cohort (1963-2016): Outcomes from a large single-center series. ( 29233628 )
2017
44
Corticosteroids for renal scar prevention in children with acute pyelonephritis. ( 28404702 )
2017
45
Role of antioxidant defence, renal toxicity markers and inflammatory cascade in disease progression of acute pyelonephritis in experimental rat model. ( 28578087 )
2017
46
Qualitative and quantitative radiological analysis of non-contrast CT is a strong indicator in patients with acute pyelonephritis. ( 29055617 )
2017
47
Xanthogranulomatous pyelonephritis presenting as acute pleuritic chest pain: a case report. ( 28399929 )
2017
48
Definitions of Complicated Urinary Tract Infection and Pyelonephritis. ( 27986671 )
2017
49
Xanthogranulomatous pyelonephritis: a case with rare adhesion to pancreas. ( 29177841 )
2017
50
Emphysematous Pyelonephritis and Cystitis: Unusual Adverse Events during Concurrent Chemoradiotherapy for Lung Cancer. ( 28638336 )
2017

Variations for Pyelonephritis

Expression for Pyelonephritis

Search GEO for disease gene expression data for Pyelonephritis.

Pathways for Pyelonephritis

Pathways related to Pyelonephritis according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CCL2 CRP CXCL8 CXCR1 CXCR2 IL10
2
Show member pathways
13.82 CCL2 CXCL8 CXCR1 CXCR2 IL10 IL1B
3
Show member pathways
13.66 CCL2 CXCL8 CXCR1 CXCR2 IL10 IL1B
4
Show member pathways
13.51 CCL2 CXCL8 IL10 IL1B IL6 PGF
5
Show member pathways
13.38 CCL2 CXCL8 CXCR1 CXCR2 IL10 IL1B
6
Show member pathways
13.3 CCL2 CXCL8 CXCR1 CXCR2 IL10 IL1B
7
Show member pathways
13 CCL2 CXCL8 IL1B IL6 TLR4 TNF
8
Show member pathways
12.85 CXCL8 IL10 IL1B IL6 TNF
9
Show member pathways
12.83 CCL2 CXCL8 IL1B IL6 TLR4 TNF
10
Show member pathways
12.72 IL1B IL6 PGF TLR4 TNF
11
Show member pathways
12.63 IL10 IL1B IL6 TLR4 TNF
12
Show member pathways
12.62 CCL2 IL10 IL1B IL6 TNF
13
Show member pathways
12.55 CXCL8 IL6 TLR4 TNF
14 12.54 CCL2 IL10 IL1B TNF
15
Show member pathways
12.43 IL10 IL1B IL6 TNF
16
Show member pathways
12.39 CCL2 CXCL8 IL1B IL6 TNF
17
Show member pathways
12.36 ALB CCL2 CRP IL1B IL6 TNF
18
Show member pathways
12.32 CXCL8 IL1B IL6 TLR4 TNF
19
Show member pathways
12.29 CXCL8 IL6 TLR4 TNF
20 12.29 IL10 IL1B IL6 TLR4 TNF
21
Show member pathways
12.28 IL10 IL1B TLR4 TNF
22
Show member pathways
12.25 ACE CCL2 CXCL8 IL10 IL1B IL6
23
Show member pathways
12.24 CXCL8 IL1B IL6 TLR4 TNF
24 12.23 CXCL8 IL10 IL1B IL6 TNF
25
Show member pathways
12.21 CXCL8 IL10 IL1B IL6 TNF
26
Show member pathways
12.04 CCL2 CXCL8 CXCR1 CXCR2
27 12.01 CCL2 CXCL8 IL1B IL6 TLR4 TNF
28 12 CCL2 IL1B IL6 TNF
29
Show member pathways
11.99 IL10 IL1B IL6 TLR4 TNF
30 11.97 IL10 IL6 TNF
31 11.97 CCL2 CXCL8 IL10 IL1B IL6 TNF
32 11.96 CCL2 CXCL8 IL1B IL6 TNF
33 11.94 CXCL8 IL1B TLR4 TNF
34 11.93 CXCL8 IL1B IL6
35 11.89 IL1B IL6 TNF
36 11.89 CXCL8 IL1B IL6 TLR4
37
Show member pathways
11.87 CXCL8 IL6 TLR4
38 11.86 CXCL8 IL10 IL1B IL6 TLR4 TNF
39
Show member pathways
11.85 IL1B IL6 TLR4
40 11.82 IL10 IL1B IL6 TNF
41 11.79 IL10 IL1B TNF
42 11.76 IL10 IL6 TLR4 TNF
43 11.75 CCL2 CXCL8 IL1B IL6 TLR4 TNF
44
Show member pathways
11.73 CXCL8 IL1B IL6 TNF
45 11.69 CCL2 CXCL8 IL1B IL6 TNF
46 11.62 CXCL8 IL1B IL6 TLR4 TNF
47 11.61 CXCL8 IL10 IL1B IL6 TLR4 TNF
48 11.59 CXCL8 CXCR1 IL6
49 11.59 CCL2 IL1B TLR4 TNF
50 11.53 IL1B IL6 TNF

GO Terms for Pyelonephritis

Cellular components related to Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 ACE ALB CCL2 CRP CXCL8 IL10
2 extracellular space GO:0005615 9.32 ACE ALB CCL2 CRP CXCL8 IL10

Biological processes related to Pyelonephritis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 chemotaxis GO:0006935 9.91 CCL2 CXCL8 CXCR1 CXCR2
2 activation of MAPK activity GO:0000187 9.88 IL1B TLR4 TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 IL1B IL6 TLR4 TNF
4 defense response to Gram-positive bacterium GO:0050830 9.87 CRP IL6 TNF
5 positive regulation of angiogenesis GO:0045766 9.87 CXCL8 CXCR2 IL1B PGF
6 immune response GO:0006955 9.87 CCL2 CXCL8 IL10 IL1B IL6 TLR4
7 cellular response to organic cyclic compound GO:0071407 9.85 CCL2 IL1B TNF
8 positive regulation of JNK cascade GO:0046330 9.85 IL1B TLR4 TNF
9 response to glucocorticoid GO:0051384 9.83 IL10 IL6 TNF
10 humoral immune response GO:0006959 9.83 CCL2 IL6 TNF
11 positive regulation of DNA binding transcription factor activity GO:0051091 9.83 IL10 IL1B IL6 TNF
12 protein kinase B signaling GO:0043491 9.81 CCL2 IL1B TNF
13 regulation of receptor activity GO:0010469 9.8 CCL2 CXCL8 IL10 IL1B IL6 PGF
14 positive regulation of interferon-gamma production GO:0032729 9.79 IL1B TLR4 TNF
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.79 IL1B TLR4 TNF
16 chemokine-mediated signaling pathway GO:0070098 9.78 CCL2 CXCL8 CXCR1 CXCR2
17 receptor internalization GO:0031623 9.77 CXCL8 CXCR1 CXCR2
18 neutrophil chemotaxis GO:0030593 9.76 CCL2 CXCL8 CXCR2 IL1B
19 negative regulation of lipid catabolic process GO:0050995 9.72 IL1B TNF
20 positive regulation of interleukin-8 production GO:0032757 9.72 IL1B TLR4 TNF
21 dendritic cell chemotaxis GO:0002407 9.71 CXCR1 CXCR2
22 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.71 IL1B TNF
23 positive regulation of macrophage activation GO:0043032 9.71 IL10 TLR4
24 negative regulation of growth of symbiont in host GO:0044130 9.71 IL10 TNF
25 negative regulation of interleukin-6 production GO:0032715 9.71 IL10 TLR4 TNF
26 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.7 IL1B TNF
27 induction of positive chemotaxis GO:0050930 9.7 CXCL8 PGF
28 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.7 CCL2 TLR4
29 positive regulation of leukocyte chemotaxis GO:0002690 9.7 CXCR2 IL6
30 response to molecule of bacterial origin GO:0002237 9.69 CXCL8 IL10
31 PERK-mediated unfolded protein response GO:0036499 9.69 CCL2 CXCL8
32 positive regulation of NF-kappaB import into nucleus GO:0042346 9.69 IL1B TLR4 TNF
33 neutrophil activation GO:0042119 9.68 CXCL8 CXCR2
34 neutrophil mediated immunity GO:0002446 9.68 ACE IL6
35 positive regulation of chemokine biosynthetic process GO:0045080 9.67 IL1B TNF
36 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.67 TLR4 TNF
37 endothelial cell apoptotic process GO:0072577 9.67 IL10 TNF
38 positive regulation of chemokine production GO:0032722 9.67 IL6 TLR4 TNF
39 positive regulation of interleukin-6 production GO:0032755 9.67 IL1B IL6 TLR4 TNF
40 regulation of establishment of endothelial barrier GO:1903140 9.66 IL1B TNF
41 positive regulation of MHC class II biosynthetic process GO:0045348 9.66 IL10 TLR4
42 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 IL10 TNF
43 positive regulation of fever generation GO:0031622 9.64 IL1B TNF
44 sequestering of triglyceride GO:0030730 9.62 IL1B TNF
45 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL10 IL1B TNF
46 receptor biosynthetic process GO:0032800 9.59 IL10 TNF
47 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 IL1B TNF
48 negative regulation of lipid storage GO:0010888 9.58 CRP IL6 TNF
49 interleukin-8-mediated signaling pathway GO:0038112 9.56 CXCR1 CXCR2
50 lipopolysaccharide-mediated signaling pathway GO:0031663 9.46 CCL2 IL1B TLR4 TNF

Molecular functions related to Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 C-X-C chemokine receptor activity GO:0016494 9.26 CXCR1 CXCR2
2 interleukin-8 binding GO:0019959 9.16 CXCR1 CXCR2
3 cytokine activity GO:0005125 9.1 CCL2 CXCL8 IL10 IL1B IL6 TNF
4 interleukin-8 receptor activity GO:0004918 8.96 CXCR1 CXCR2

Sources for Pyelonephritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....